A comparison of incidence and risk factors for serious adverse events in rheumatoid arthritis patients with etanercept or adalimumab in Korea and Japan

References

• Baldini C, Delle Sedie A, Bombardieri S. From clinical trials to the bedside: how can we treat patients with rheumatoid arthritis and concurrent morbidities who are generally excluded from randomised controlled clinical trials?. Clin Exp Rheumatol. 2005;23(6):893–904.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Jain A, Askling J, Bridges SL Jr, Carmona L, Dixon W, et al. A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum. 2010;40(1):2–14.e1.
   PubMed Web of Science ®Google Scholar
• Dixon WG, Symmons DP, Lunt M, Watson KD, Hyrich KL, Silman AJ. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: Lessons from interpreting data from observational studies. Arthritis Rheum. 2007;56(9):2896–904.
   PubMed Web of Science ®Google Scholar
• Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis. 2007;66(10):1339–44.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum. 2007;56(4):1125–33.
   PubMed Web of Science ®Google Scholar
• Zink A, Askling J, Dixon WG, Klareskog L, Silman AJ, Symmons DP. European biologicals registers: methodology, selected results and perspectives. Ann Rheum Dis. 2009;68(8):1240–6.
   PubMed Web of Science ®Google Scholar
• Cho SK, Sung YK, Choi CB, Uhm WS, Kim TH, Jun JB, et al. Treatment Persistence with TNF Blocker in Korean Rheumatoid Arthritis Patients. J Rheum Dis. 2011;18(3):161–7.
   Google Scholar
• Sakai R, Tanaka M, Nanki T, Watanabe K, Yamazaki H, Koike R, et al. to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules. Ann Rheum Dis. 2012;71(11):1820–6.
   PubMed Web of Science ®Google Scholar
• Sakai R, Komano Y, Tanaka M, Nanki T, Koike R, Nagasawa H, et al. Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(8):1125–34.
   PubMed Web of Science ®Google Scholar
• Cho SK, Sung YK, Choi CB, Bae SC. Impact of comorbidities on TNF inhibitor persistence in rheumatoid arthritis patients: an analysis of Korean National Health Insurance claims data. Rheumatol Int. 2012;32(12):3851–6.
   PubMed Web of Science ®Google Scholar
• Komano Y, Tanaka M, Nanki T, Koike R, Sakai R, Kameda H, et al. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety. J Rheumatol. 2011;38(7):1258–64.
   PubMed Web of Science ®Google Scholar
• Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function–measured and estimated glomerular filtration rate. N Engl J Med. 2006;354(23):2473–83.
   PubMed Web of Science ®Google Scholar
• WHO. Nutritional anemia: report of a WHO scientific group. WHO Techn Rep Ser. 1968;405:1–37.
   Google Scholar
• Koike R, Takeuchi T, Eguchi K, Miyasaka N; Japan College of Rheumatology. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol. 2007;17(6):451–8.
   PubMedGoogle Scholar
• Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005;52(11):3403–12.
   PubMed Web of Science ®Google Scholar
• The Korean National Statistical Office, Korean Statistical Information Service, http://www.kosis.kr/eng/database/database_001000.jsp?listid = A&subtitle = Population/Household#jsClick. (cited; Available from: http://www.kosis.kr/abroad/abroad_01List.jsp?parentId = A [accessed 15 November 2011])
   Google Scholar
• Ministry of Internal Affairs and communications, Statistical Bureau, Director-General for Policy Planning (Statistical Standards) & Statistical Research and Training Insutitute, http://www.stat.go.jp/data/jinsui/2011np/index.htm (cited; Available from: http://www.stat.go.jp/data/jinsui/2011np/index.htm [accessed 15 November 2011])
   Google Scholar
• Yamagiwa K, Iijima S, Furuya T, Ikai T, Inoue E, Taniguchi A, et al. Incidence of falls and fear of falling in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2011;21(1):51–6.
   PubMed Web of Science ®Google Scholar
• Sung YK, Cho SK, Choi CB, Park SY, Shim J, Ahn JK, et al. Korean Observational Study Network for Arthritis (KORONA): establishment of a prospective ulticenter cohort for rheumatoid arthritis in South Korea. Semin Arthritis Rheum. 2012;41(6):745–51.
   PubMed Web of Science ®Google Scholar
• Strangfeld A, Eveslage M, Schneider M, Bergerhausen HJ, Klopsch T, Zink A, Listing J. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?. Ann Rheum Dis. 2011;70(11):1914–20.
   PubMed Web of Science ®Google Scholar
• Schneeweiss S, Setoguchi S, Weinblatt ME, Katz JN, Avorn J, Sax PE, et al. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum. 2007;56(6):1754–64.
   PubMed Web of Science ®Google Scholar
• Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum. 2006;54(2):628–34.
   PubMed Web of Science ®Google Scholar
• Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, et al. Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2011;21(4):343–51.
   PubMed Web of Science ®Google Scholar
• Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, et al. Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. Ann Rheum Dis. 2011;70(12):2148–51.
   PubMed Web of Science ®Google Scholar
• Nagurney JT, Brown DF, Sane S, Weiner JB, Wang AC, Chang Y. The accuracy and completeness of data collected by prospective and retrospective methods. Acad Emerg Med. 2005;12(19):884–95.
   PubMedGoogle Scholar
• Soliman MM, Ashcroft DM, Watson KD, Lunt M, Symmons DP, Hyrich KL; British Society for Rheumatology Biologics Register. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011;70(4):583–9.
   PubMed Web of Science ®Google Scholar